Details of the Drug

General Information of Drug (ID: DMSCDY9)

Drug Name
Mannitol
Synonyms
Diosmol; Hexahydroxyhexane; Invenex; Isotol; MTL; Manita; Mannazucker; Mannidex; Mannigen; Mannistol; Mannit; Mannite; Osmitrol; Osmofundin; Osmosal; Resectisol; Cordycepic acid; Cpd without stereochemical designation; Manna sugar; Mannitol [USAN]; Marine Crystal; Resectisol In Plastic Container; M0044; Mannidex 16700; Mannogem 2080; D-mannite; D-mannitol; DL-Mannitol; MANNITOL 25%; Maniton-S; Mannitol (USP); Mannitol (VAN); Mannitol 10%; Mannitol 10% In Plastic Container; Mannitol 15%; Mannitol 15% In Plastic Container; Mannitol 20%; Mannitol 20% In Plastic Container; Mannitol 5%; Mannitol 5% In Plastic Container; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); Osmitrol 10% In Water; Osmitrol 15% In Water; Osmitrol 20% In Water; Osmitrol 5% In Water; SDM No. 35; SORBITOL-MANNITOL IN PLASTIC CONTAINER; Sorbitol-Mannitol; D-Mannitol (JP15); MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; D-(-)-Mannitol; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; MANNITOL 15% DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; MANNITOL 5% DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; (L)-Mannitol
Indication
Disease Entry ICD 11 Status REF
Bronchiectasis CA24 Approved [1]
Cerebral edema 8D60.1 Approved [2]
Cystic fibrosis CA25 Approved [2]
Edema MG29 Approved [2]
Ocular hypertension 9C61.01 Approved [2]
Pseudotumor cerebri N.A. Approved [2]
Renal failure GB60-GB6Z Approved [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Sweetening Agents
Affected Organisms
Humans and other mammals
ATC Code
A06AD16: Mannitol
A06AD: Osmotically acting laxatives
A06A: DRUGS FOR CONSTIPATION
A06: DRUGS FOR CONSTIPATION
A: ALIMENTARY TRACT AND METABOLISM
B05BC01: Mannitol
B05BC: Solutions producing osmotic diuresis
B05B: I.V. SOLUTIONS
B05: BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B: BLOOD AND BLOOD FORMING ORGANS
B05CX04: Mannitol
B05CX: Other irrigating solutions
B05C: IRRIGATING SOLUTIONS
B05: BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B: BLOOD AND BLOOD FORMING ORGANS
R05CB16: Mannitol
R05CB: Mucolytics
R05C: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
R05: COUGH AND COLD PREPARATIONS
R: RESPIRATORY SYSTEM
V04CX04: Mannitol
V04CX: Other diagnostic agents
V04C: OTHER DIAGNOSTIC AGENTS
V04: DIAGNOSTIC AGENTS
V: VARIOUS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 182.17
Logarithm of the Partition Coefficient (xlogp) -3.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 73.15 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 13.71 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5 h [3]
Clearance
The renal clearance of drug is 4.4 L/h [3]
Elimination
Following oral inhalation of 635 mg of mannitol in healthy volunteers, 55% of the total dose was recovered unchanged in the urine; following oral or intravenous administration of 500 mg, the corresponding values were 54 and 87%, respectively [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.7 hours [3]
Metabolism
The drug is metabolized via the liver []
Vd
The volume of distribution (Vd) of drug is 34.3 L [3]
Chemical Identifiers
Formula
C6H14O6
IUPAC Name
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Canonical SMILES
C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
InChIKey
FBPFZTCFMRRESA-KVTDHHQDSA-N
Cross-matching ID
PubChem CID
6251
ChEBI ID
CHEMBL16899
CAS Number
69-65-8
UNII
3OWL53L36A
DrugBank ID
DB00742
TTD ID
D0P7EK
VARIDT ID
DR00859
INTEDE ID
DR2323
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH) TTTX5M8 M2DH_ASPFU Activator [4]
Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA) TTV0PE2 MTLD_ASPFU Activator [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
H(+)/Cl(-) exchange transporter 3 (CLCN3) OTEEXNMU CLCN3_HUMAN Drug Response [5]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Gene/Protein Processing [6]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Gene/Protein Processing [7]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Gene/Protein Processing [7]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mannitol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Framycetin DMF8DNE Major Increased risk of nephrotoxicity by the combination of Mannitol and Framycetin. Alcoholic liver disease [DB94] [8]
Kanamycin DM2DMPO Major Increased risk of nephrotoxicity by the combination of Mannitol and Kanamycin. Bacterial infection [1A00-1C4Z] [8]
Streptomycin DME1LQN Major Increased risk of nephrotoxicity by the combination of Mannitol and Streptomycin. Bacterial infection [1A00-1C4Z] [8]
Gentamicin DMKINJO Major Increased risk of nephrotoxicity by the combination of Mannitol and Gentamicin. Bacterial infection [1A00-1C4Z] [8]
Netilmicin DMRD1QK Major Increased risk of nephrotoxicity by the combination of Mannitol and Netilmicin. Bacterial infection [1A00-1C4Z] [8]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Mannitol and Levomilnacipran. Chronic pain [MG30] [9]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Mannitol and Sertraline. Depression [6A70-6A7Z] [9]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Mannitol and Vilazodone. Depression [6A70-6A7Z] [9]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Mannitol and Vortioxetine. Depression [6A70-6A7Z] [9]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Mannitol and Desvenlafaxine. Depression [6A70-6A7Z] [9]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Mannitol and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [10]
Digitoxin DMWVIGP Moderate Increased risk of hypomagnesemia by the combination of Mannitol and Digitoxin. Heart failure [BD10-BD1Z] [11]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Mannitol and Captopril. Hypertension [BA00-BA04] [12]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Mannitol and Perindopril. Hypertension [BA00-BA04] [12]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Mannitol and Quinapril. Hypertension [BA00-BA04] [12]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Mannitol and Sibutramine. Obesity [5B80-5B81] [9]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Mannitol and Plazomicin. Urinary tract infection [GC08] [8]
⏷ Show the Full List of 17 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016080.
2 Mannitol FDA Label
3 FDA Approved Drug Products: BRONCHITOL (mannitol) oral inhalation powder
4 Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82.
5 Differential expression and roles of volume-activated chloride channels in control of growth of normal and cancerous nasopharyngeal epithelial cells. Biochem Pharmacol. 2012 Feb 1;83(3):324-34. doi: 10.1016/j.bcp.2011.11.007. Epub 2011 Nov 18.
6 [Plasma levels of atrial natriuretic factor (ANF) in the stroke patients after glycerol and mannitol infusion]. Zhonghua Yi Xue Za Zhi (Taipei). 1990 Aug;46(2):86-90.
7 Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
8 Athlin L, Domellof L, Holm S "Gentamicin treatment in severe surgical infections: serum levels, interactions, toxicity and efficacy." Acta Chir Scand 147 (1981): 225-30. [PMID: 7034430]
9 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
10 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
11 Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
12 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]